Log In Sign up
The largest database of trusted experimental protocols

Anti ccr6 bv605

Manufactured by BioLegend
Visit Supplier

Anti-CCR6 BV605 is a fluorophore-conjugated antibody that binds to the CCR6 receptor. CCR6 is a chemokine receptor that plays a role in the recruitment of T cells and dendritic cells. The BV605 fluorophore allows for flow cytometric detection and analysis of CCR6-expressing cells.

Automatically generated - may contain errors

Lab products found in correlation

Anti cxcr3 fitc, by BioLegend (3 mentions) Anti cd3 bv711, by BioLegend (2 mentions) Anti cd69 pe, by BioLegend (2 mentions) Anti cd28 apc, by BioLegend (2 mentions) Anti cd45ro bv711, by BioLegend (2 mentions) Anti ccr4 bv421, by BioLegend (2 mentions) Anti ccr7 bv650, by BioLegend (2 mentions) Anti cd16 pe, by Thermo Fisher Scientific (1 mentions) Live dead aqua, by Thermo Fisher Scientific (1 mentions) Anti cd3 percp cy5, by Thermo Fisher Scientific (1 mentions) Anti cd14 alexafluor647, by BioLegend (1 mentions) Cd86 fitc, by Thermo Fisher Scientific (1 mentions) Anti ccr4 pe cy7, by BioLegend (1 mentions) Anti cd161 bv421, by BioLegend (1 mentions) Anti hla dr pe cy7, by Thermo Fisher Scientific (1 mentions) Anti cd8 apc, by Thermo Fisher Scientific (1 mentions) Lsrfortessa, by BD (1 mentions) Anti cd25 pe, by BD (1 mentions) Anti cd80 bv421, by BioLegend (1 mentions) Anti icos pe, by BioLegend (1 mentions)

Close spelling variants of this product

Anti-CCR6 (5 citations) BV605-CCR6 (4 citations)

4 protocols using anti ccr6 bv605

1

Jurkat T Cell Phenotyping by Flow

Check if the same lab product or an alternative is used in the 5 most similar protocols
Jurkat T cells were stimulated under indicated conditions. About half a million cells per condition were harvested, washed and incubated with fluorophore-conjugated antibodies for 20 min at room temperature in MACS buffer (DBPS without calcium and magnesium, supplemented with 1% FBS). Cells were washed and resuspended in MACS buffer and analyzed by flow cytometry in corresponding fluorescent channels relative to unstained control. Antibodies used: anti-CD69 PE, anti-CD28 APC, anti-CD3 BV711, anti-CD45RO BV711, anti-CXCR3 FITC, anti-CCR4 BV421, anti-CCR6 BV605, and/or anti-CCR7 BV650 antibodies (all diluted 1:100 and from Biolegend).
Agosto L.M., Mallory M.J., Ferretti M.B., Blake D., Krick K.S., Gazzara M.R., Garcia B.A, & Lynch K.W. (2023). Alternative splicing of HDAC7 regulates its interaction with 14-3-3 proteins to alter histone marks and target gene expression. Cell reports, 42(3), 112273.
+ Open protocol
+ Expand
2

Jurkat T Cell Phenotyping by Flow

Check if the same lab product or an alternative is used in the 5 most similar protocols
Jurkat T cells were stimulated under indicated conditions. About half a million cells per condition were harvested, washed and incubated with fluorophore-conjugated antibodies for 20 min at room temperature in MACS buffer (DBPS without calcium and magnesium, supplemented with 1% FBS). Cells were washed and resuspended in MACS buffer and analyzed by flow cytometry in corresponding fluorescent channels relative to unstained control. Antibodies used: anti-CD69 PE, anti-CD28 APC, anti-CD3 BV711, anti-CD45RO BV711, anti-CXCR3 FITC, anti-CCR4 BV421, anti-CCR6 BV605, and/or anti-CCR7 BV650 antibodies (all diluted 1:100 and from Biolegend).
Agosto L.M., Mallory M.J., Ferretti M.B., Blake D., Krick K.S., Gazzara M.R., Garcia B.A, & Lynch K.W. (2023). Alternative splicing of HDAC7 regulates its interaction with 14-3-3 proteins to alter histone marks and target gene expression. Cell reports, 42(3), 112273.
+ Open protocol
+ Expand
3

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
3x106 PBMCs were stained with Live/Dead Aqua (Life Technologies) and antibodies specific for the following human markers: anti-CD3-PercP-Cy5.5 (eBioscience), anti-CD20-Brillian Violet (BV)421 (eBioscience), anti-CD4-AlexaFluor700/PercP-Cy5.5 (eBioscience), anti-CD8-APC (eBioscience), anti-CD25-PE (BD), anti-CD14- AlexaFluor647 (BioLegend), anti-CD16-PE (eBioscience), anti-CXCR3-FITC (BioLegend), anti-CCR4-PECy-7 (BioLegend), anti-CCR6-BV605 (BioLegend) anti-CD161-BV421 (BioLegend), anti-CD45RA APCy-7 (BioLegend), anti-HLA-DR PECy7 (eBioscience), anti-CD80 CCR6-BV650 (BioLegend), CD86-FITC (Invitrogen) and CD163-APC/Cy7 (BioLegend) for 30min at 4°C. Cells were acquired on an LSR-Fortessa (BD) with consistent application settings, internal assay-control, fluorescence minus ones (FMO) control, isotype controls and/or biological control. Data was analysed using FlowJo (Tree Star, Inc. OR, USA) with gating strategies provided in the supplemental material.
Nova-Lamperti E., Romano M., Christakoudi S., Runglall M., McGregor R., Mobillo P., Kamra Y., Tsui T.L., Norris S., John S., Boardman D.A., Lechler R.I., Lombardi G, & Hernandez-Fuentes M.P. (2018). Reduced TCR-signalling contributes to impaired Th17 responses in tolerant kidney transplant recipients. Transplantation, 102(1), e10-e17.
+ Open protocol
+ Expand
4

Comprehensive Immunophenotyping of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Anti-CD19 APC-Cy7, anti-CD38 PerCp-Cy5.5, anti-CD4 PE-Cy7, anti-CD25 PerCP-Cy5.5, anti-CD86 APC, anti-CD80 BV421, anti-CD45RA BV605, anti-ICOS PE, anti-CD21 PE-Cy7, anti-CD80 BV421, anti-CD27 PerCp-Cy5.5, anti-PD-1 APC, anti-CD45RA APC-Cy7, anti-HLA-DR BV605, anti-CD11c AF700, anti-CD86 BV711, anti-CD95 BV650, anti-IgD BV786, anti-FCRL5 APC, anti-CXCR3 BV421, anti-CCR6 BV605, anti-CD19 BV650, anti-CD19 BV605, anti-PD-L1 BV421, anti-PD-L2 PE, anti-ICOS-L PE, anti-OX40L PE, anti-IL-10 PE, anti-IL-10 APC, anti-TNF-α APC-Cy7 (all obtained from BioLegend); anti-IgD FITC and anti-IgD PE (both from Southern Biotech); anti-CD27 PE (Dako); and anti-CD21 PE-Cy7, anti-CD69 FITC, anti-HLA-DR FITC, anti-CD27 BV605, anti-CD40 FITC, anti-CD40L PE, anti-ICAM-1 PE, anti-CXCR5 BUV395 and anti-CD27 BUV395 (all from BD Biosciences).
Reincke M.E., Payne K.J., Harder I., Strohmeier V., Voll R.E., Warnatz K, & Keller B. (2020). The Antigen Presenting Potential of CD21low B Cells. Frontiers in Immunology, 11, 535784.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!